ASP Isotopes (NASDAQ:ASPI) CEO Sells $694,353.82 in Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CEO Paul Elliot Mann sold 83,758 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $8.29, for a total value of $694,353.82. Following the transaction, the chief executive officer directly owned 9,663,424 shares in the company, valued at approximately $80,109,784.96. This represents a 0.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paul Elliot Mann also recently made the following trade(s):

• On Wednesday, June 3rd, Paul Elliot Mann sold 83,759 shares of ASP Isotopes stock. The stock was sold at an average price of $7.76, for a total transaction of $649,969.84.

ASP Isotopes Stock Down 15.8%

ASP Isotopes stock opened at $6.71 on Friday. The firm has a market cap of $844.79 million, a price-to-earnings ratio of -3.23 and a beta of 3.42. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.39 and a quick ratio of 4.37. ASP Isotopes Inc. has a fifty-two week low of $3.92 and a fifty-two week high of $14.49. The firm has a fifty day moving average price of $5.54 and a two-hundred day moving average price of $5.87.

ASP Isotopes (NASDAQ:ASPI) last released its earnings results on Wednesday, May 20th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06. The firm had revenue of $8.36 million during the quarter, compared to analyst estimates of $3.68 million. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%.

Analyst Ratings Changes

ASPI has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research report on Friday, March 27th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a research report on Tuesday, April 14th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $13.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC raised its position in ASP Isotopes by 12.4% in the third quarter. ProShare Advisors LLC now owns 13,101 shares of the company’s stock worth $126,000 after purchasing an additional 1,448 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its position in ASP Isotopes by 8.3% in the third quarter. Mercer Global Advisors Inc. ADV now owns 21,056 shares of the company’s stock worth $203,000 after purchasing an additional 1,622 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in ASP Isotopes by 9.9% in the second quarter. The Manufacturers Life Insurance Company now owns 20,840 shares of the company’s stock worth $153,000 after purchasing an additional 1,878 shares in the last quarter. Legal & General Group Plc grew its stake in ASP Isotopes by 30.4% during the third quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock worth $81,000 after buying an additional 1,953 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of ASP Isotopes by 84.9% during the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after buying an additional 2,548 shares in the last quarter. Institutional investors and hedge funds own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.